Company insight
Addressing latent TB infection in the immunosuppressed
Dr Edoardo Carretto, the director of clinical microbiology at Santa Maria Nuova Hospital, located in Reggio Emilia, Italy, sheds light on the pivotal role of the T-SPOT.TB test from Revvity in combating cases of latent TB infection, and how it is leading the charge towards the constant reduction of TB cases within the province.
I
n the quest to support the World Health Organisation’s (WHO) ‘End TB Strategy’, which aims to reduce global TB incidence by 80% by 2030, the detection of latent TB infection (LTBI) is key. As an active member of the local TB prevention and control programme for the region, Dr Edoardo Carretto is an advocate for the importance of screening for LTBI, particularly in the immunosuppressed population. This prompted the adoption of the WHO-recommended T-SPOT.TB test, an interferon-gamma release assay (IGRA).
Reliable by design The T-SPOT.TB test is a sensitive blood test to detect LTBI. Through isolation, washing, and counting of the PBMCs, the accuracy of patient results is enhanced. “Prior to using the T-SPOT.TB test, some of our results were equivocal mainly in immunosuppressed populations. With the normalisation of T cells in the T-SPOT.TB test, more than 80% of patients with
The T-SPOT.TB test’s automated workfl ow steps make previous labour-intensive tasks, like cell isolation or spot counting, both easy and rapid.
labour-intensive tasks, like cell isolation or spot counting, both easy and rapid. Now
“The main advantages come with the automated workfl ow steps, which make previous labour- intensive tasks, like cell isolation or spot counting, both easy and rapid.”
previously ‘indeterminate’ results are now detected,” Carretto notes.
Commenting on the choice of the T-SPOT. TB test, Carretto says, “The T-SPOT.TB test has significantly improved our TB testing workflow, allowing the maximum efficiency in our Reggio Emilia lab. The main advantages come with the automated workflow steps, which make previous
22
that the TB testing workflow is more technician-friendly, we have been able to process far more samples, and identify LTBI with greater accuracy and reliability.”
Looking ahead
Having been actively engaged in the battle against TB, Carretto is optimistic about the future. Before the Covid-19
outbreak, in 2019, the TB rate in Italy was down to 5.5 per 100,000 population. With an increased number of testing regimes such as that of Reggio Emilia, and further simplifications of the transformative T-SPOT.TB test workflow, the WHO’s target of an 80% reduction in new TB cases by 2030 could now be achieved. ●
Products may not be licensed in accordance with the laws in all countries. Please check with your local representative for availability. Revvity, Inc. does not endorse or make recommendations with respect to research, medication or treatments. All information presented is for informational purposes only and is not intended as medical advice.
www.tspot.com/uk Practical Patient Care /
www.practical-patient-care.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61
